Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


07.08.2017

1 AJR Am J Roentgenol
2 Am J Respir Crit Care Med
1 Ann Surg Oncol
1 BMC Cancer
1 Br J Cancer
4 Cancer Chemother Pharmacol
2 Cancer Lett
2 Cancer Res
2 Clin Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
1 Int J Cancer
1 J Cancer Res Clin Oncol
2 J Clin Oncol
1 J Thorac Cardiovasc Surg
2 J Thorac Oncol
1 Lung Cancer (Auckl)
1 Oncogene
1 Oncol Rep
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. LIANG M, Yip R, Tang W, Xu D, et al
    Variation in Screening CT-Detected Nodule Volumetry as a Function of Size.
    AJR Am J Roentgenol. 2017 Jun 1:1-5. doi: 10.2214/AJR.16.17159.
    PubMed     Text format     Abstract available


    Am J Respir Crit Care Med

  2. ROMAN J
    On the "TRAIL" of a Killer: MMP12 in Lung Cancer.
    Am J Respir Crit Care Med. 2017;196:262-264.
    PubMed     Text format    

  3. FIELDING D, Dalley AJ, Bashirzadeh F, Singh M, et al
    Next-Generation Sequencing of Endobronchial Ultrasound Transbronchial Needle Aspiration Specimens in Lung Cancer.
    Am J Respir Crit Care Med. 2017;196:388-391.
    PubMed     Text format    


    Ann Surg Oncol

  4. SEOK Y, Kang HG, Lee SY, Jeong JY, et al
    Polymorphisms in Epithelial-Mesenchymal Transition-Related Genes and the Prognosis of Surgically Treated Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2017 Aug 1. doi: 10.1245/s10434-017-6002.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  7. REN K, Xu R, Huang J, Zhao J, et al
    Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2017;80:243-250.
    PubMed     Text format     Abstract available

  8. ZHAO XM, Zhao J, Wu XH, Luo ZG, et al
    Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Cancer Chemother Pharmacol. 2017 Jul 28. doi: 10.1007/s00280-017-3399.
    PubMed     Text format     Abstract available

  9. KENMOTSU H, Ohde Y, Wakuda K, Nakashima K, et al
    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3400.
    PubMed     Text format     Abstract available

  10. IMAI H, Sugiyama T, Tamura T, Minemura H, et al
    A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3403.
    PubMed     Text format     Abstract available


    Cancer Lett

  11. TONG CWS, Wu WKK, Loong HHF, Cho WCS, et al
    Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.
    Cancer Lett. 2017 Jul 31. pii: S0304-3835(17)30459.
    PubMed     Text format     Abstract available

  12. NERI S, Miyashita T, Hashimoto H, Suda Y, et al
    Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma.
    Cancer Lett. 2017;395:20-30.
    PubMed     Text format     Abstract available


    Cancer Res

  13. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
    RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
    Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
    PubMed     Text format     Abstract available

  14. DU W, Xu X, Niu Q, Zhang X, et al
    Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
    Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  15. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
    PubMed     Text format     Abstract available


  16. Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
    Clin Cancer Res. 2017;23:4523.
    PubMed     Text format    


    Clin Lung Cancer

  17. SONNICK MA, Oro F, Yan B, Desai A, et al
    Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
    Clin Lung Cancer. 2017 Jul 6. pii: S1525-7304(17)30206.
    PubMed     Text format     Abstract available


    Eur J Cancer

  18. SU C, Zhou F, Shen J, Zhao J, et al
    Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challen
    Eur J Cancer. 2017;83:266-278.
    PubMed     Text format     Abstract available


    Int J Cancer

  19. GUPTA SK, Guzman EAT, Meenach SA
    Co-administration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
    Int J Cancer. 2017 Aug 2. doi: 10.1002/ijc.30913.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  20. MININA VI, Soboleva OA, Glushkov AN, Voronina EN, et al
    Polymorphisms of GSTM1, GSTT1, GSTP1 genes and chromosomal aberrations in lung cancer patients.
    J Cancer Res Clin Oncol. 2017 Aug 2. doi: 10.1007/s00432-017-2486.
    PubMed     Text format     Abstract available


    J Clin Oncol

  21. TEMEL JS, Greer JA, El-Jawahri A, Pirl WF, et al
    Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2017;35:834-841.
    PubMed     Text format     Abstract available

  22. SPIGEL DR, Edelman MJ, O'Byrne K, Paz-Ares L, et al
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    J Clin Oncol. 2017;35:412-420.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  23. FERNANDEZ FG
    What are the gaps in quality measurement for lung cancer surgery?
    J Thorac Cardiovasc Surg. 2017 Jul 1. pii: S0022-5223(17)31367.
    PubMed     Text format    


    J Thorac Oncol

  24. FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
    Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
    PubMed     Text format    

  25. ZHANG X, Liu Y, Shao H, Zheng X, et al
    Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
    J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  26. SEETHARAMU N, Preeshagul IR, Sullivan KM
    New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
    Lung Cancer (Auckl). 2017;8:67-78.
    PubMed     Text format     Abstract available


    Oncogene

  27. VELMURUGAN KR, Varghese RT, Fonville NC, Garner HR, et al
    High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  28. WANG D, Cao Q, Qu M, Xiao Z, et al
    MicroRNA-616 promotes the growth and metastasis of non-small cell lung cancer by targeting SOX7.
    Oncol Rep. 2017 Jul 28. doi: 10.3892/or.2017.5854.
    PubMed     Text format     Abstract available


    PLoS One

  29. GONG X, Liu J, Zhang D, Yang D, et al
    GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    PLoS One. 2017;12:e0182410.
    PubMed     Text format     Abstract available

  30. LIU L, He Y, Ge G, Li L, et al
    Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study.
    PLoS One. 2017;12:e0182168.
    PubMed     Text format     Abstract available

  31. PELAEZ R, Morales X, Salvo E, Garasa S, et al
    beta3 integrin expression is required for invadopodia-mediated ECM degradation in lung carcinoma cells.
    PLoS One. 2017;12:e0181579.
    PubMed     Text format     Abstract available

  32. MIRET M, Horvath-Puho E, Deruaz-Luyet A, Sorensen HT, et al
    Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.
    PLoS One. 2017;12:e0181564.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: